Defining the Functional Role of NaV1.7 in Human Nociception

Authors: Lucy McDermott, Greg A. Weir, Andreas C. Themistocleous, Andrew R. Segerdahl, Iulia Blesneac, Georgios Baskozos, Alex Clark, Val Millar, Liam J Peck, Daniel Ebner, Irene Tracey, Jordi Serra, David Bennett - Neuron 2019 cited by 208

1.7 blockers undergoing clinical trials lack specificity. CIP, therefore, arises due to a profound loss of functional nociceptors, which is more pronounced than that reported in rodent models, or likely achievable following acute pharmacological blockade. VIDEO ABSTRACT.